Tumor-associated B7-H1 molecules inhibit antitumor immunity in some malignancies. We found that B7-H1 expression on patient myeloma cells and human myeloma cell lines (HMCLs) was upregulated by cultivating the cells with autologous stromal cells and the human stromal cell line HS-5. Among major cytokines produced by HS-5 cells, interleukin (IL)-6-induced B7-H1 expression on HMCLs. Moreover, HS-5 cell-mediated B7-H1 expression was downregulated by inhibiting IL-6. B7-H1
INTRODUCTION
B7-H1 (CD274), which was identified by us as a co-stimulatory molecule, has a crucial role in T-cell regulation in various immune responses.
1,2 B7-H1 molecules deliver a costimulatory signal through an unknown receptor on naive T cells. [1] [2] [3] [4] They also deliver an inhibitory signal to activated T cells through programmed cell death 1 (PD-1) molecules, 5 which are a type I transmembrane protein belonging to the CD28 receptor family and were originally identified in T cells undergoing apoptosis. 6 Recent studies have also shown that B7-H1 utilizes another receptor, CD80, to transmit an inhibitory signal to T cells. 7, 8 B7-H1 expression is detected not only on antigen-presenting cells but also on activated T cells and some tumor cells (that is, renal cell, colon, breast, and lung carcinoma and Hodgkin lymphoma). [9] [10] [11] [12] [13] In these tumors, tumor-associated B7-H1 molecules may evade immune cells, including tumor-specific cytotoxic T lymphocytes (CTLs). Moreover, B7-H1 expression may be induced on the tumor cell surface by cytokines, which are commonly involved in the antitumor immune response. We reported that interferon (IFN)-g and tumor necrosis factor-a, which are often overproduced in myelodysplastic syndromes (MDS), induced B7-H1 expression on MDS blasts.
14 Furthermore, MDS blasts expressing B7-H1 had greater intrinsic proliferative capacity than B7-H1
À MDS blasts and were capable of inducing T-cell apoptosis.
Multiple myeloma (MM) is an incurable B-cell neoplasm characterized by an uncontrolled expansion of neoplastic plasma cells, called myeloma cells, in the bone marrow (BM). Soluble factors, such as interleukin (IL)-6 secreted by BM stromal cells, and direct contact between myeloma cells and BM stromal cells and/or the marrow extracellular matrix are important for myeloma cell proliferation. 15, 16 Such direct contact enhances IL-6 and vascular endothelial growth factor production by stromal cells. It was also reported that circulating levels of IFN-g, tumor necrosis factor-a, IL-1b and IL-6 are often increased in MM patients. 17 A previous study reported that expression levels of B7-H1 on plasma cells from MM patients were higher than those on cells from healthy donors and patients with monoclonal gammopathy of undetermined significance (MGUS). Furthermore, this expression was increased or induced by IFN-g and toll-like receptor ligands in vitro through the MEK/ERK pathway. 18 In another study, both primary myeloma cells from patients and myeloma cell lines had a small subpopulation of plasma cells, which expressed CD34, CD138, Ki67, and B7-H1. 19 However, it remains largely unknown whether and how B7-H1 molecules have a role in the pathophysiology of MM. In this study, we investigated whether the BM microenvironment induces B7-H1 expression on myeloma cells, which are associated with not only immune evasion but also drug resistance and an intrinsic proliferative advantage in MM.
MATERIALS AND METHODS

Cell lines and patients
The human myeloma cell lines (HMCLs), KMM-1, KMS-11, KMS-12BM, KMS-12PE, KMS-18, KMS-20, KMS-26, KMS-27, KMS-28BM, KMS-28PE, KMS-34 (kindly provided by Dr Otsuki, Kawasaki Medical School, Okayama, Japan), RPMI8226 and U266 (American Type Culture Collection (ATCC), Manassas, VA, USA) were maintained in complete medium, that is, RPMI1640 supplemented with 10% FCS, 2 mmol/l L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. PCM6 myeloma cells (Riken Cell Bank, Tsukuba, Japan) were maintained in McCoy's 5A modified medium (Life Technologies, Carlsbad, CA, USA) containing 20% FCS and 3 ng/ml of recombinant human IL-6 (Kirin Brewery Co., Tokyo, Japan). 20 The human BM stromal cell line HS-5 was obtained from the ATCC. 21 In some experiments, B7-H1 þ and B7-H1 À myeloma cells were purified with FACSVantage (BD Biosciences, San Jose, CA, USA), as described previously. 20 The cell number was counted using the trypan blue dye-exclusion method.
BM samples were obtained from individuals who underwent BM aspiration for diagnostic purposes after obtaining written informed consent. The diagnoses were made according to the International Myeloma Working Group criteria. 22 The individuals included 40 patients with newly diagnosed MM, 16 MGUS patients and 10 hematologically normal individuals. The Durie and Salmon 23, 24 staging and the International Scoring System staging systems were used for MM patients according to previous reports. In some MM patients, BM samples (or peripheral blood (PB), if there were circulating myeloma cells) were obtained also when their MM relapsed or became refractory to the standard chemotherapy. This study protocol was approved by the Institutional Review Board of Nippon Medical School. Mononuclear cells were separated from BM or PB samples with Histopaque (Sigma-Aldrich, St. Louis, MO, USA) density centrifugation. These cells were used immediately or cryopreserved in liquid nitrogen until use. Primary stromal cells from MM patients were prepared, as previously described. 20 Reverse-transcription and real-time PCR Total cellular RNA was extracted from cultured cells using Isogen (Takara Bio, Shiga, Japan) and reverse-transcribed with Superscript II Reverse transcriptase (Life Technologies) using random hexamers. The success of cDNA synthesis was monitored by the reverse-transcription PCR of b-actin. PCR analysis using primers for B7-H1 was performed, as described previously. 25 In some experiments, purified B7-H1 þ and B7-H1 À RPMI8226 cells were used for the RNA source and their gene expression of Bad, Bax, Bcl-2, Bcl-xL, Mcl-1, caspase-3, caspase-8, caspase-9, FADD, Fas and FasL were examined using real-time PCR with SYBR Premix Ex Taq II (Takara Bio) and the 7500 fast real-time PCR system (Life Technologies), as described previously. 26 The primers employed are shown in Supplementary Table S1 .
Flow cytometric analyses
Immunophenotyping was performed using flow cytometry (FCM), as reported previously. 14, 20 In brief, cells of interest were treated with human immunoglobulin (MP Biomedicals, Solon, OH, USA) before staining to block nonspecific binding of antibodies. When analyzing HMCLs, the cells were stained with anti-B7-H1-phycoerythrin (PE), anti-PD-1-fluorescein isothiocyanate (FITC) (eBiosience, San Diego, CA, USA), anti-CD80-PE, and/or anti-FasL-PE (BD Biosciences). For intracellular Bcl-2 staining, the cells were fixed and permeabilized with Cytofix/Cytoperm (BD Biosciences) before staining for anti-Bcl-2-FITC (BD Biosciences). The cell samples from patients and hematologically normal individuals were stained with anti-CD45-peridin chlorophyll, anti-CD38-FITC (BD Biosciences), and anti-B7-H1-PE. Plasma cells were identified as a cell population with markedly high expression of CD38, as described previously. 20 We confirmed that the indentified plasma cells expressed another plasma cell marker, CD138 (BD Biosciences). Isotype-matched negative controls for FITC-and PE-conjugated antibodies were used.
Coculture with stromal cells, their culture supernatant and cytokines Figure S1a) . Similarly, MM cells from patients were cocultured with autologous stromal cells, as reported previously. 20 For the transwell assay, 1 Â 10 5 HMCL cells were plated onto a transwell membrane insert (BD Biosciences) placed above the culture containing no cells, HS-5 cells alone or an HS-5/HMCL cell mixture. After 2-day culture at 37 1C, the HMCL cells above the transwell membrane were subjected to FCM analysis.
For analyzing the soluble factor(s) produced by HS-5 cells, HMCL cells were cultured for 2-3 days in the presence of HS-5 cell culture supernatant or various cytokines that HS-5 cells produce, that is, IL-6, IL-8, granulocytecolony stimulating factor and macrophage inflammatory protein 1 alpha (R&D Systems, Minneapolis, MN, USA). 21 In some experiments, an antihuman IL-6 polyclonal antibody (R&D Systems) was used to neutralize the biological activities of IL-6. To inhibit signal transduction, 1 Â 10 5 HMCL cells were preincubated for 2 h with the following inhibitors, STAT3 inhibitor V (500 nM), U0126 (20 mM), AG490 (25 mM) or PDTC (10 mM; Merck, Darmstadt, Germany), and then incubated with recombinant human IL-6 (10 ng/ml). After 3 h, the cells were washed with complete medium and cultured for 24 h before FCM analysis. Concentrations of IFN-a and -g in the HS-5 cell culture supernatants were measured using enzyme-linked immunosorbent assay kits (eBiosience).
Cell-cycle, bromodeoxyuridine and Ki67 analyses
For cell-cycle analysis, HMCLs were stained with anti-B7-H1-PE and then fixed in 70% cold ethanol at 4 1C for 3 h. After washing, the cells were stained with propidium iodide (PI, Sigma-Aldrich) and the cell cycle of B7-H1 þ and B7-H1 À cells was analyzed using FCM. 14, 26 For bromodeoxyuridine (BrdU) analysis, the cells were pulsed with 10 mM BrdU (BrdU flow kit; BD Biosciences) for 1 h, washed and stained with anti-B7-H1-PE. Then, the cells were permeabilized and stained with anti-BrdU-FITC according to the manufacturer's instructions. For Ki67 analysis, cells were stained with anti-B7-H1-PE, washed, permeabilized with 75% ethanol and stained with anti-Ki67-FITC (FITC mouse anti-human Ki67 set; BD Biosciences) according to the manufacturer's instructions. BrdU incorporation and Ki67 staining were determined using FCM.
14 Mixed lymphocyte-myeloma reaction and cytotoxic assay using CTLs
CD3
þ T cells were purified from PB from healthy volunteers using magnetic-activated cell sorting (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). The purity of the isolated cells was 495%, as determined in FCM. These cells (1 Â 10 5 cells/well) were cocultured with irradiated (20000 rad) HMCL cells in 96-well U-bottomed plates. In some cultures, antagonistic anti-B7-H1 (eBioscience) or anti-PD-1 (R&D Systems) antibody was added to block the B7-H1-PD-1 pathway. After 5 days, the cells were subjected to apoptosis analysis: the cells were stained with anti-CD3-PE and with annexin V-FITC and PI (Trevigen, Gaithersburg, MD, USA) according to the manufacturer's instructions and then analyzed using FCM.
14 For generating CTLs, 5 Â 10 6 nonadherent PBMCs from normal individuals were cocultured with 5 Â 10 5 irradiated (20 000 rad) KMS-27 cells for 7 days in a medium containing RPMI1640 supplemented with L-glutamine (2 mm), penicillin (100 mg/ml), streptomycin (100 mg/ml) and 15% human AB serum. After eliminating dead cells by Ficoll-Hypaque centrifugation, viable cells were cultured at 5 Â 10 5 /ml and restimulated with irradiated KMS-27 cells in the presence of IL-2 (10 U/ml, R&D Systems). After 7 days, CD8 þ T cells were purified using magnetic-activated cell sorting. The CTLs obtained were cocultured with target cells, which were untreated KMS-27 cells or KMS-27 cells on which B7-H1 expression was induced by IFN. In some cultures, an antagonistic anti-B7-H1 antibody (R&D Systems) was added to block the B7-H1-mediated signal. After 4 h, cytotoxicity was evaluated by measuring lactate dehydrogenase (LDH) activity released into the medium of this coculture. LDH activity was measured with the CytoTox96 nonradioactive assay (Promega, Madison, WI, USA) according to the manufacturer's instructions.
Analysis of drug-induced apoptosis
HMCLs were exposed to dexamethasone and melphalan (Sigma-Aldrich) at concentrations optimal for inducing apoptosis (15 and 10 mM, respectively). 27, 28 After 2 days, the cells were harvested and stained with anti-B7-H1-PE, annexin-V-FITC, and PI and analyzed using FCM.
B7-H1-transfected and mock KMS-28PE cells
KMS-28PE cells, which were shown in RT-PCR not to express B7-H1 mRNA, were transfected with a human B7-H1.pcDNA3 plasmid using the FuGENE6 transfection reagent (Roche Diagnostics, Basel, Switzerland).
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The transfected cells were cultured with complete medium containing 1 mg/ml G418 (Life Technologies) and subsequently isolated as a single clone by limiting dilution. B7-H1-expressing KMS-28PE cells (B7-H1.KMS-28PE) were identified using FCM. KMS-28PE cells transfected with a pcDNA vector (mock.KMS-28PE) were used as negative controls.
Statistical analysis
Differences between two groups of data were determined using the w 2 test for categorical variables and Mann-Whitney U-test for continuous variables. P values of o0.05 were considered statistically significant.
RESULTS
Expression and induction of B7-H1 molecules on HMCLs First, we analyzed the expression of B7-H1 molecules in 14 HMCLs. Although B7-H1 mRNA expression was detected in 9 of 14 HMCLs using RT-PCR (Figure 1a ), only 4 cell lines, KMS-12BM, KMS-34, RPMI8226 and U266, expressed cell-surface B7-H1 in 5% or more cells in FCM. In all HMCLs examined, cell-surface B7-H1 expression was induced or enhanced by IFN-g (Supplementary Table S2 ), as expected from the fact that IFN-g is the main inducer of B7-H1 expression in normal cells and some solid tumors. We then examined the expression of two B7-H1 receptors, PD-1 and CD80, in all the HMCLs using RT-PCR and FCM. PD-1 mRNA and protein were detected in RPMI8226 cells alone, and CD80 mRNA and protein were detected in KMM-1, KMS-27, KMS-28PE, KMS-34 and RPMI8226 cells (data not shown). We next compared B7-H1 expression between CD138 þ and CD138 À populations in HMCLs, of which the latter are more immature cells compared with the former. The expression levels were higher in the CD138 À populations in the two cell lines examined, that is, RPMI8226 and KMS-20 cells (Supplementary Figure S1b) .
Next, we examined whether stromal cells could induce/enhance B7-H1 expression on HMCLs. When HMCLs were cocultured with the human stromal cell line HS-5, cell-surface B7-H1 expression was induced/enhanced in all the five HMCLs examined (data from three cell lines are shown in Figure 1b) . Then, we performed transwell experiments in which HMCLs were placed in the upper chamber and no cells (medium alone), HS-5 cells or a combination of HS-5 cells and HMCLs were placed in the lower chambers ( Figure 1c) . The results demonstrated that an HS-5 cell-derived soluble factor(s) enhanced B7-H1 expression on HMCLs and the elaboration of the factor(s) did not require cell-cell contact between HS-5 cells and HMCLs.
IL-6 is a major product of HS-5 stromal cells, which induces B7-H1 expression on HMCLs HS-5 cells did not produce significant amounts of IFN-g and -a, as reported previously 29 and confirmed in this study by analyzing the HS-5 culture supernatant (both were undetectable in enzymelinked immunosorbent assay). To identify the main product of HS-5 cells, which induces/enhances B7-H1 expression on HMCLs, we first examined whether major cytokines produced by HS-5 cells, that is, IL-6, IL-8, granulocyte-colony stimulating factor and macrophage inflammatory protein 1 alpha, 21 could induce B7-H1 expression on HMCLs. Among these cytokines, IL-6 alone enhanced cell-surface B7-H1 expression on all HMCLs examined (Supplementary Figure S1c) , and this enhancement was dose dependent (Figure 2a) . The ability of IL-6 to induce B7-H1 expression was comparable to or less than that in HS-5 culture supernatants, depending on the HMCL examined (data from three cell lines are shown in Figure 2b ). This B7-H1-inducing effect in the supernatants was inhibited, at least partially, by an antagonistic antibody to IL-6 ( Figure 2c ). As expected, the IL-6-induced B7-H1 expression on HMCLs was downregulated by inhibiting molecules involved in the IL-6 signal cascade, STAT3, MEK1/2 or JAK2, but not by inhibiting NKkB, which is often involved in IFN-g-mediated B7-H1 induction (Figure 2d ).
B7-H1
þ myeloma cells show an intrinsic growth advantage and downregulate antimyeloma immunity We investigated whether HMCLs expressing B7-H1 molecules on their surface had a proliferative advantage over B7-H1 À HMCLs, as documented previously in MDS cell lines and in B7-H1-transduced cells. First, we examined RPMI8226 cells as they contain a sizable B7-H1 þ cell fraction without any stimulation. B7-H1 þ RPMI8226 cells had fewer G 0 /G 1 -phase cells and more G 2 /M-phase cells compared with B7-H1 À RPMI8226 cells (Figure 3a, left panel) . When cell-surface B7-H1 expression was induced by IL-6 in the other three HMCLs, the same cell-cycle advantage seen in B7-H1 þ cells was documented in each. The data from KMS-34 cells are shown in Figure 3a (right panel) . Furthermore, in the two HMCLs examined, untreated RPMI8226 cells and KMS-34 cells treated with IL-6, B7-H1 þ cells showed higher levels of BrdU incorporation compared with B7-H1 À cells (Figure 3b) . Finally, the percentage of Ki67 þ cells was much higher in B7-H1 þ fraction than in the B7-H1
À fraction in RPMI8226 cells (Figure 3c ). Consistent with these results, when B7-H1 þ and B7-H1 À RPMI8226 cells were isolated by FCM and cultured, B7-H1 þ cells proliferated more rapidly than B7-H1 À cells (Figure 3d ). Next, we examined whether B7-H1 þ myeloma cells could modulate antimyeloma immunity. When B7-H1-expressing RPMI8226 cells were cocultured with normal lymphocytes, the cells induced lymphocyte apoptosis, and this induction was almost completely blocked by inhibiting the B7-H1 and PD-1 pathway (Figure 3e ). Moreover, we generated KMS-27 cell-specific CTLs and found that KMS-27 myeloma cells lacking B7-H1 expression were killed by the CTLs. However, by inducing B7-H1 molecules on the KMS-27 cell surface, KMS-27 cells showed almost complete resistance to the apoptotic effect of CTLs (Figure 3f) . Furthermore, this resistance was abolished by blocking B7-H1 molecules.
Relationship between B7-H1 expression and drug sensitivity in HMCLs When RPMI8226 cells were treated with the antimyeloma agents dexamethasone and melphalan (Figure 4a , left panel), these agents induced marked apoptosis in the B7-H1
À cell fraction but not in the B7-H1 þ cell fraction. We then transduced the B7-H1 gene into KMS-28PE cells lacking B7-H1 expression. The antimyeloma agents induced apoptosis in mock-transduced KMS-28PE cells, but showed little activity in B7-H1-transduced KMS-28PE cells (Figure 4a, right panel) . The results for PI þ cells in the above experiments are shown in Supplementary Figure S2 .
We then compared gene expression levels of apoptosis-related proteins between B7-H1 þ and B7-H1 À RPMI8226 cells using realtime PCR. B7-H1 þ cells had markedly higher levels of Bcl-2 and FasL expression compared with B7-H1 À cells (Figure 4b ). Consistent with these results, B7-H1 þ RPMI8226 cells had higher levels of intracellular Bcl-2 and cell-surface FasL proteins compared with B7-H1 À RPMI8226 cells (Figure 4c ).
Characteristics of B7-H1-expressing MM patients B7-H1 expression levels on plasma cells from newly diagnosed MM patients (n ¼ 40), patients with MGUS (n ¼ 16), and normal individuals (n ¼ 10) were analyzed. The plasma cells from normal individuals lacked B7-H1 expression, whereas those from MM patients often expressed B7-H1 molecules and their expression levels were higher compared with cells from MGUS patients (Figure 5a ), consistent with a previous report. 18 Next, we compared patient characteristics between 10 MM patients whose myeloma cells were highly positive for B7-H1 (20% or more myeloma cells were B7-H1 þ , called B7-H1 high þ MM) and other 30 MM patients (called B7-H1
À /low MM) ( Table 1) . Two parameters relating to myeloma cell mass in vivo, percentages of myeloma cells in the BM and serum LDH levels, were higher in Stromal-induced B7-H1 expression on myeloma cells H Tamura et al
high þ MM patients than in B7-H1 À /low MM patients. B7-H1 expression levels on myeloma cells tended to be higher in MM patients with International Scoring System stage II/III than those with International Scoring System stage I disease, although this difference did not reach statistical significance (Figure 5b) . Furthermore, B7-H1 expression levels were often upregulated when patients relapsed or became refractory to anti-MM chemotherapy (Figure 5c ).
Finally, we examined whether autologous stromal cells generated from MM patients could modulate B7-H1 expression on patient myeloma cells. In all patients examined, B7-H1 expression on myeloma cells was upregulated after the cells were cultivated with autologous stromal cells (Figure 5d ).
DISCUSSION
Blocking the B7-H1/PD-1 pathway, for example, with anti-PD-1 antibody, may enhance antitumor immune responses and has been proposed as a potential new immunotherapy in some malignancies. [30] [31] [32] Meanwhile, there are few data on the expression and function of B7-H1 molecules in myeloma. In particular, it is not known whether and how B7-H1 molecules have a role in the pathophysiology of this intractable disease. In the current study, we demonstrated that (1) B7-H1 expression on MM cells is induced by BM stromal cells, and this induction is, at least in part, because of IL-6 produced by stromal cells in the cell-line work, and that (2) compared with B7-H1 À HMCLs, B7-H1 þ HMCLs have greater proliferative potential and are less susceptible to apoptosis by dexamethasone and melphalan, accompanied by higher expression levels of Bcl-2 and FasL. It is notable that high levels of Bcl-2 expression on myeloma cells were associated with clinically aggressive behavior and drug resistance in previous studies. 33 Furthermore, we found that, among newly diagnosed MM patients, patients whose myeloma cells expressed high levels of B7-H1 were associated with high percentages of myeloma cells in the BM and high serum LDH levels, the latter of which is a
B7-H1
-actin marker of drug resistance and short survival in MM. 34, 35 Consistently, the B7-H1 expression levels on a patient's myeloma cells become higher when MM patients relapse or become refractory to anti-MM chemotherapy.
The interaction between myeloma cells and the BM microenvironment is crucial in the pathophysiology of the disease. BM stromal cells produce various cytokines including IL-6, insulin-like growth factor, vascular endothelial growth factor and B-cell activating factor. This interaction, as well as IL-6 alone, augments myeloma cell growth, survival and drug resistance. 16 IL-6 is a major cytokine involved in myeloma pathophysiology, although it is probably not indispensable for myeloma growth in vivo. For example, myeloma cells gain a growth advantage and drug resistance independent of IL-6 signaling by interacting with stromal cells. 36 Moreover, clinical trials using anti-IL-6 antibodies have not yielded promising results. Similarly, IL-6 may be not indispensable for B7-H1 induction on myeloma cells, as anti-IL-6 antibody did not completely abolish the induction in the cell line experiments (Figure 2 ) and in experiments using primary myeloma cells and autologous stromal cells (data not shown), and there are other cytokines, such as IFNs, which can induce B7-H1 expression on myeloma cells in vivo. It is considered that signals delivered by the interaction between BM stromal and myeloma cells are numerous and complex. 37 It was reported that the expression of CD28 and its ligand B7.2 (CD86) on myeloma cells was associated with more aggressive disease and that CD28 expression on myeloma cells was induced by stromal cells. [38] [39] [40] Those data in conjunction with the data in this study support the concept that the interaction between myeloma and stromal cells induces expression of multiple B7-family molecules on myeloma cells and is associated with aggressive disease.
We showed that B7-H1-expressing HMCLs had a proliferative advantage over their B7-H1 À counterparts, as observed previously in MDS cell lines. The mechanism of this phenomenon has not been clarified; however, the presence of a reverse signal, that is, a signal from B7-H1 molecules on the tumor cell surface backward into the cell, was reported in experiments using B7-H1 þ P815 murine mastocytoma cells. 41 This reverse signal rendered B7-H1 þ P815 cells resistant to T cell-mediated killing and apoptosis induced by Fas ligation. The intracellular domain of the B7-H1 molecule, which has 30 amino acids, does not contain any obvious motifs for signaling to known anti-apoptotic molecules, including Bcl-2. This domain may act by binding an adaptor molecule that delivers antiapoptotic signals. It was reported that a fraction of myeloma cells expresses both B7.2 and its receptor CD28, which may create a self-stimulatory mechanism. 39 We could not verify myeloma infiltrates in the BM of patients, 42 and that the number of dendritic cells within myeloma cell infiltrates were increased in refractory MM patients. 39 Moreover, it was reported that PD-1 expression was increased on T cells isolated from MM patients. 30 Therefore, when B7-H1 molecules are induced on myeloma cells by the interaction with stromal cells, these molecules may interact with CD80 or PD-1 on other cells in the BM. Further studies are needed to elucidate fully the B7-H1-CD80/PD-1 interaction in the BM microenvironment in myeloma.
As the B7-H1/PD-1 pathway has an important role in downregulating T-cell function and evading the host antitumor immune response, at least in some malignancies, immunotherapies modulating this pathway are expected to be beneficial. 43 In a murine acute myeloid leukemia (AML) model, blocking B7-H1 molecules increased the proliferation and function of AML-specific CTLs at tumor sites. Although the anti-AML effect was limited, the combination of such blocking and depletion of regulatory T cells demonstrated superior efficacy in eradicating AML. 44 In humans, a phase I study using an anti-PD-1 antagonistic antibody showed tumor regression in a fraction of patients with solid tumors. 45 Blocking the B7-H1 pathway in myeloma patients may be beneficial. However, we emphasize that B7-H1 molecules on myeloma cells are linked to the dual activity of inducing T-cell downregulation and enhancing aggressive myeloma-cell characteristics that include increased proliferative ability and drug resistance, and thus blocking the signal to T cells alone may be insufficient. Furthermore, as the growth advantage of B7-H1 þ cells is also observed in another malignancy, that is, MDS, we recommend examining whether the dual activity of B7-H1 molecules is exerted in other malignancies, particularly when designing clinical trials targeting this molecule. In summary, to the best of our knowledge, this is the first report showing that the BM microenvironment induces B7-H1 expression on myeloma cells. In addition to the T-cell inhibitory effect, B7-H1 molecules on myeloma cells are associated with aggressive cell behavior, including increased proliferative potential and resistance to chemotherapeutic drugs. B7-H1-mediated signals may be involved in the pathophysiology of myeloma, and modulating this pathway may have therapeutic potential in myeloma patients. 
